
Robert Genta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4157239/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab. Clinical Gastroenterology and Hepatology, 2022, 20, 535-545.e15.	4.4	28
2	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). Journal of Allergy and Clinical Immunology, 2022, 149, 659-670.	2.9	40
3	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clinical Gastroenterology and Hepatology, 2022, 20, 2474-2484.e3.	4.4	57
4	The Occurrence of Gastritis in Microscopic Colitis and Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2022, , .	4.4	0
5	Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field. Journal of Allergy and Clinical Immunology, 2022, 149, 844-853.	2.9	10
6	Quantification of Mucosal Eosinophils for the Histopathologic Diagnosis of Eosinophilic Gastritis and Duodenitis. American Journal of Surgical Pathology, 2022, 46, 557-566.	3.7	18
7	Nonâ€oesophageal eosinophilic gastrointestinal diseases are undersuspected clinically and underdiagnosed pathologically. Alimentary Pharmacology and Therapeutics, 2022, 56, 240-250.	3.7	13
8	Mast Cell and Eosinophil Counts in Gastric and Duodenal Biopsy Specimens From Patients With and Without Eosinophilic Gastroenteritis. Clinical Gastroenterology and Hepatology, 2021, 19, 2102-2111.	4.4	39
9	The Meaning of Incidental Goblet Cells at the Gastroesophageal Junction. Digestive Diseases and Sciences, 2021, 66, 1588-1592.	2.3	1
10	Comorbid Occurrence of Eosinophilic Esophagitis and Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 613-615.e1.	4.4	14
11	Comparison of Culture With Antibiogram to Next-Generation Sequencing Using Bacterial Isolates and Formalin-Fixed, Paraffin-Embedded Gastric Biopsies. Gastroenterology, 2021, 161, 1433-1442.e2.	1.3	38
12	Collagenous gastritis: Epidemiology and clinical associations. Digestive and Liver Disease, 2021, 53, 1136-1140.	0.9	9
13	621 PL02.05 LONG-TERM TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC DUODENITIS WITH LIRENTELIMAB, A MONOCLONAL ANTIBODY AGAINST SIGLEC-8. Ecological Management and Restoration, 2021, 34, .	0.4	0
14	620 GASTRODUODENAL EOSINOPHILIA IS UNDER-APPRECIATED IN EOSINOPHILIC ESOPHAGITIS (EOE) PATIENTS WITH FUNCTIONAL BOWEL SYMPTOMS: A REAL LIFE EXPERIENCE. Ecological Management and Restoration, 2021, 34, .	0.4	0
15	Lymphocytic gastritis and its relationships with other gastrointestinal disorders. Alimentary Pharmacology and Therapeutics, 2021, 54, 1170-1178.	3.7	7
16	619 HIGH DISCOVERY RATE OF GASTRODUODENAL EOSINOPHILIA BUT NOT EOSINOPHILIC ESOPHAGITIS IN PATIENTS WITH CHRONIC GASTROINTESTINAL SYMPTOMS. Ecological Management and Restoration, 2021, 34, .	0.4	0
17	Editorial: lymphocytic gastritis and its relationships with other gastrointestinal disorders—authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 1356-1356.	3.7	0
18	Not All Autoimmune Gastritis Are Created the Same. Gastroenterology Research, 2021, 14, 348-349.	1.3	4

#	Article	IF	CITATIONS
19	Seasonal Variation of Duodenal Intraepithelial Lymphocytosis. Clinical Gastroenterology and Hepatology, 2020, 18, 2136-2138.e1.	4.4	4
20	Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. New England Journal of Medicine, 2020, 383, 1624-1634.	27.0	173
21	Prevalence and concordant occurrence of esophageal, gastric, duodenal, and colonic eosinophilia. Ecological Management and Restoration, 2020, 33, .	0.4	4
22	Autoimmune gastritis. Nature Reviews Disease Primers, 2020, 6, 56.	30.5	156
23	Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. New England Journal of Medicine, 2019, 381, 1513-1523.	27.0	178
24	Quantification of the duodenal eosinophil content in adults: a necessary step for an evidenceâ€based diagnosis of duodenal eosinophilia. Alimentary Pharmacology and Therapeutics, 2018, 47, 1143-1150.	3.7	22
25	Gene expression-phenotype associations in adults with eosinophilic esophagitis. Digestive and Liver Disease, 2018, 50, 804-811.	0.9	15
26	Editorial: the postâ€ <i>Helicobacte</i> r stomach—not the same for cohorts and individuals. Alimentary Pharmacology and Therapeutics, 2018, 47, 846-847.	3.7	2
27	Upfront Alcian Blue-periodic acid Schiff stain for the assessment of upper gastrointestinal disorders. Digestive and Liver Disease, 2018, 50, 417-418.	0.9	2
28	Associations of Microscopic Colitis With Other Lymphocytic Disorders of the Gastrointestinal Tract. Clinical Gastroenterology and Hepatology, 2018, 16, 1762-1767.	4.4	36
29	Unde venis ? Geographic profiling for the prevention of gastricÂcancer. Gastrointestinal Endoscopy, 2018, 87, 1029-1030.	1.0	0
30	Regional Patterns of Olmesartan Prescription and theÂPrevalence of Duodenal Villous Atrophy Throughout theÂUnitedÂStates. Clinical Gastroenterology and Hepatology, 2018, 16, 584-585.	4.4	2
31	OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. American Journal of Gastroenterology, 2018, 113, 1621-1628.	0.4	96
32	Primary Colonic Eosinophilia and Eosinophilic Colitis in Adults. American Journal of Surgical Pathology, 2017, 41, 225-233.	3.7	93
33	Gastric Cancer as Preventable Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 1833-1843.	4.4	162
34	Demographic and socioeconomic influences on <i>Helicobacter pylori</i> gastritis and its preâ€neoplastic lesions amongst <scp>US</scp> residents. Alimentary Pharmacology and Therapeutics, 2017, 46, 322-330.	3.7	22
35	Editorial: the diminishing returns of normalisation of the oesophageal mucosa. Alimentary Pharmacology and Therapeutics, 2017, 46, 71-72.	3.7	1
36	Routine Antiâ€ <i>Helicobacter</i> Immunohistochemical Staining is Significantly Superior to Reflex Staining Protocols for the Detection of <i>Helicobacter</i> in Gastric Biopsy Specimens. Helicobacter, 2016, 21, 581-585.	3.5	19

#	Article	IF	CITATIONS
37	Chronicles of a cancer foretold: 35â€years of gastric cancer risk assessment. Gut, 2016, 65, 721-725.	12.1	72
38	Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes. JAMA - Journal of the American Medical Association, 2016, 315, 2104.	7.4	190
39	Ethnic Variations in Duodenal Villous Atrophy Consistent WithÂCeliac Disease in the United States. Clinical Gastroenterology and Hepatology, 2016, 14, 1105-1111.	4.4	37
40	Macroscopy predicts tumor progression in gastric cancer: A retrospective patho-historical analysis based on Napoleon Bonaparte's autopsy report. Digestive and Liver Disease, 2016, 48, 1378-1385.	0.9	5
41	Order and Chaos in the World of Serrated Polyps. Journal of Clinical Gastroenterology, 2016, 50, 187-188.	2.2	0
42	The coeliac stomach: gastritis in patients with coeliac disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 180-187.	3.7	66
43	Characteristics of the Gastric Mucosa in Patients With Intestinal Metaplasia. American Journal of Surgical Pathology, 2015, 39, 700-704.	3.7	20
44	Ethnic Distribution of Microscopic Colitis in the United States. Inflammatory Bowel Diseases, 2015, 21, 2634-2639.	1.9	25
45	Helicobacter infections with rare bacteria or minimal gastritis: Expecting the unexpected. Digestive and Liver Disease, 2015, 47, 549-555.	0.9	20
46	Changes in the Gastric Mucosa With Aging. Clinical Gastroenterology and Hepatology, 2015, 13, 2276-2281.	4.4	51
47	Prevalence of benign gastric polyps in a large pathology database. Digestive and Liver Disease, 2015, 47, 164-169.	0.9	43
48	High Prevalence of Gastric Preneoplastic Lesions in East Asians and Hispanics in the USA. Digestive Diseases and Sciences, 2015, 60, 2070-2076.	2.3	50
49	Epithelial Dysplasia and Cancer in IBD Strictures. Journal of Crohn's and Colitis, 2015, 9, 769-775.	1.3	28
50	<i>Helicobacter</i> â€negative gastritis: a distinct entity unrelated to <i>Helicobacter pylori</i> infection. Alimentary Pharmacology and Therapeutics, 2015, 41, 218-226.	3.7	42
51	Big data in gastroenterology research. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 386-390.	17.8	23
52	Liver histology of acute brucellosis caused by Brucella melitensis. Human Pathology, 2014, 45, 2023-2028.	2.0	42
53	Autoimmune atrophic gastritis—pathogenesis, pathology and management. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 529-541.	17.8	285
54	Decreased Risk of Celiac Disease in Patients With Helicobacter pylori Colonization. American Journal of Epidemiology, 2013, 178, 1721-1730.	3.4	133

#	Article	IF	CITATIONS
55	Commentary:H. pylorieradication therapy after subtotal gastrectomy for gastric cancer - can the qualitative be quantified?. Alimentary Pharmacology and Therapeutics, 2013, 38, 989-990.	3.7	1
56	Reactive gastropathy is associated with inflammatory conditions throughout the gastrointestinal tract. Alimentary Pharmacology and Therapeutics, 2012, 36, 736-743.	3.7	25
57	lleal biopsy: Clinical indications, endoscopic and histopathologic findings in 10,000 patients. Digestive and Liver Disease, 2011, 43, 199-203.	0.9	51
58	Adherence to biopsy guidelines increases celiac disease diagnosis. Gastrointestinal Endoscopy, 2011, 74, 103-109.	1.0	168
59	The Los Angeles and Savary-Miller systems for grading esophagitis: utilization and correlation with histology. Ecological Management and Restoration, 2011, 24, 10-17.	0.4	54
60	Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. Modern Pathology, 2011, 24, 556-563.	5.5	157
61	Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients. Journal of Clinical Pathology, 2010, 63, 681-686.	2.0	261
62	The diagnostic value of the duodenal biopsy: A clinico-pathologic analysis of 28,000 patients. Digestive and Liver Disease, 2010, 42, 485-489.	0.9	20
63	A National Study of Helicobactor pylori Infection in Gastric Biopsy Specimens. Gastroenterology, 2010, 139, 1894-1901.e2.	1.3	190
64	The gastric mucosa in gastric cancer patients in a low-incidence area. European Journal of Gastroenterology and Hepatology, 2006, 18, 1085-1093.	1.6	5
65	Assessing risks for gastric cancer: New tools for pathologists. World Journal of Gastroenterology, 2006, 12, 5622.	3.3	17
66	Gastric mucosa: long-term outcome after cure ofHelicobacter pylori infection. Journal of Gastroenterology, 2002, 37, 17-23.	5.1	49
67	Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Alimentary Pharmacology and Therapeutics, 2002, 16, 1249-1259.	3.7	306
68	Pre-neoplastic states of the gastric mucosa-a practical approach for the perplexed clinician. Alimentary Pharmacology and Therapeutics, 2001, 15, 43-50.	3.7	25
69	Morphometric assessment of gastric antral atrophy: comparison with visual evaluation. Histopathology, 2001, 39, 235-242.	2.9	39
70	Topographic patterns of intestinal metaplasia and gastric cancer. American Journal of Gastroenterology, 2000, 95, 1431-1438.	0.4	221
71	Histologic assessment of Helicobacter pylori status after therapy: comparison of Giemsa, Diff-Quik, and Genta stains. Modern Pathology, 1998, 11, 288-91.	5.5	40
72	InvasiveHelicobacter‣ike Organisms in Feline Gastric Mucosa. Helicobacter, 1997, 2, 40-43.	3.5	10

#	Article	IF	CITATIONS
73	The immunobiology of Helicobacter pylori gastritis. Seminars in Gastrointestinal Disease, 1997, 8, 2-11.	0.8	26
74	Histological features do not define NSAID-induced gastritis. Human Pathology, 1996, 27, 1348-1354.	2.0	87
75	Classification and Grading of Gastritis. American Journal of Surgical Pathology, 1996, 20, 1161-1181.	3.7	4,403
76	p53 protein accumulation in tumors of the ampulla of Vater. Cancer, 1995, 76, 1150-1154.	4.1	34
77	Comparison of biopsy sites for the histopathologic diagnosis of Helicobacter pylori: a topographic study of H. pylori density and distribution. Gastrointestinal Endoscopy, 1994, 40, 342-345.	1.0	294
78	Southern-blot analysis and simultaneousIn Situ detection of hepatitis B virus–associated DNA and antigens in patients with end-stage liver disease. Hepatology, 1993, 18, 1032-1038.	7.3	8
79	Dysregulation of strongyloidiasis: a new hypothesis. Clinical Microbiology Reviews, 1992, 5, 345-355.	13.6	153
80	Synchronous occurrence of different polyp types during colonoscopy. Alimentary Pharmacology and Therapeutics, 0, , .	3.7	1